

- impulses in largest afferent nerve fibres to muscle. *J Neurophysiol* 1956;19:75-98.
17. Nielsen JB, Crone C, Hultborn H. The spinal pathophysiology of spasticity – from a basic science point of view. *Acta Physiol (Oxf)*. 2007;189:171-80.
  18. Denny-Brown D. The cerebral control of movement. Liverpool: Liverpool University Press, 1966.
  19. Lance JW. Symposium synopsis. I: Feldman RG, Young RR, Koella WP, red. 712 spasticity: disordered motor control. Chicago: Year Book Medical, 1980:485-94.
  20. Dietz V, Quintern J, Berger W. Electrophysiological studies of gait in spasticity and rigidity. *Brain* 1981;104:431-49.
  21. Sinkjaer T, Toft E, Larsen K et al. Non-reflex and reflex mediated ankle joint stiffness in multiple sclerosis patients with spasticity. *Muscle Nerve* 1993;16:69-76.
  22. Ashworth B. Preliminary trial of cardioprodal in multiple sclerosis. *Practitioner* 1964;192:540-2.
  23. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. *Phys Ther* 1987;67:206-7.
  24. O'Dwyer NJ, Ada L, Neilson PD. Spasticity and muscle contracture following stroke. *Brain* 1996;119:1737-49.
  25. Malhotra S, Cousins E, Ward A et al. An investigation into the agreement between clinical, biomechanical and neurophysiological measures of spasticity. *Clin Rehabil* 2008;22:1105-15.
  26. Alhusaini AA, Dean CM, Crosbie J et al. Evaluation of spasticity in children with cerebral palsy using Ashworth and Tardieu scales compared with laboratory measures. *J Child Neurol* 2010;25:1242-7.
  27. Knutsson E, Mårtensson A. Dynamic motor capacity in spastic paresis and its relation to prime mover dysfunction, spastic reflexes and antagonist coactivation. *Scand J Rehabil Med* 1980;12:93-106.
  28. Mirbagheri MM, Barbeau H, Ladouceur M et al. Intrinsic and reflex stiffness in normal and spastic, spinal cord injured subjects. *Exp Brain Res* 2001;141:446-59.
  29. Ørsnes GB, Sørensen PS, Larsen TK et al. Effect of baclofen on gait in spastic MS patients. *Acta Neurol Scand* 2000;101:244-8.
  30. Boiteau M, Malouin F, Richards CL. Use of a hand-held dynamometer and a Kin. Com dynamometer for evaluating spastic hypertonia in children: a reliability study. *Phys Ther* 1995;75:796-802.
  31. Lamontagne A, Malouin F, Richards CL et al. Evaluation of reflex- and nonreflex-induced muscle resistance to stretch in adults with spinal cord injury using hand-held and isokinetic dynamometry. *Phys Ther* 1998;78:964-75, 976-8.
  32. Lee HM, Chen JJ, Ju MS et al. Validation of portable muscle tone measurement device for quantifying velocity-dependent properties in elbow spasticity. *J Electromyogr Kinesiol* 2004;14:577-89.
  33. Prochazka A, Bennet DJ, Stephens MJ et al. Measurement of rigidity in Parkinson's disease. *Mov Disord* 1997;12:24-32.
  34. Hultborn H. Spinal reflexes, mechanisms and concepts: from Eccles to Lundberg and beyond. *Prog Neurobiol* 2006;78:215-32.
  35. Hermsdörfer J, Elias Z, Cole JD et al. Preserved and impaired aspects of feed-forward grip force control after chronic somatosensory deafferentation. *Neurorehabil Neural Repair* 2008;22:374-84.
  36. Lundbye-Jensen J, Petersen TH, Rothwell JC et al. Interference in ballistic motor learning: specificity and role of sensory error signals. *PLoS One* 2011;6:e17451.
  37. Sinkjaer T, Toft E, Hansen HJ. H-reflex modulation during gait in multiple sclerosis patients with spasticity. *Acta Neurol Scand* 1995;91:239-46.
  38. Schindler-Ivens S, Brown DA, Lewis GN et al. Soleus H-reflex excitability during pedaling post-stroke. *Exp Brain Res* 2008;188:465-74.
  39. Wang Y, Pillai S, Wolpaw JR et al. Motor learning changes GABAergic terminals on spinal motoneurons in normal rats. *Eur J Neurosci* 2006;23:141-50.
  40. Perez MA, Lundbye-Jensen J, Nielsen JB. Changes in corticospinal drive to spinal motoneurons following visuo-motor skill learning in humans. *J Physiol* 2006;573:843-55.



## LÆGEMIDDELSTYRELSEN

### TILSKUD TIL LÆGEMIDLER

Lægemedelstyrelsen meddeler, at der pr. 20. februar 2012 ydes generelt uklausuleret tilskud efter sundhedslovens § 144 til følgende lægemidler:

- (N-05-AX-12) Abilify smeltetabletter\*, Zcare4 ApS
- (R-01-AD-12) Avamys næsespray\*, Paranova Danmark A/S
- (M-01-AE-01) Brufen Retard depottabletter\*, Orifarm A/S
- (B-01-AC-22) Efiend tabletter\*, EuroPharmaDK ApS
- (G-03-GA-05) Gonal-f injektionsvæske\*, Abacus Medicine A/S
- (N-03-AF-03) Inovelon tabletter\*, Orifarm A/S
- (A-10-BD-07) Janumet tabletter\*, Paranova Danmark A/S
- (A-10-BH-01) Januvia tabletter\*, Abacus Medicine A/S
- (A-10-AE-04) Lantus Optiset injektionsvæske\*, Abacus Medicine A/S
- (A-10-AE-04) Lantus Solo Star injektionsvæske\*, Abacus Medicine A/S
- (S-01-ED-51) Latiotim øjendråber\*, Sandoz A/S

- (C-09-DA-01) Losartan/Hydrochlorothiazide »Teva« tabletter\*, Teva Denmark A/S
- (C-09-DA-01) Losartankalium/hydrochlorothiazid tabletter\*, Zcare4 ApS
- (N-05-AX-08) Rispolept Consta depotinjektionsvæske\*, Orifarm A/S
- (A-07-EC-01) Salazopyrin tabletter\*, A-Pharma ApS
- (N-03-AF-01) Tegretol CR depottabletter\*, Orifarm A/S
- (N-05-AF-05) Zuclophenxolacetat Orifarm injektionsvæske\*, Orifarm A/S

Denne bestemmelse træder i kraft den 20. februar 2012.

\*) Omfattet af tilskudsprissystemet.